Journal
ACS NANO
Volume 17, Issue 4, Pages 3225-3258Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.2c11691
Keywords
nanotechnology; biomaterials; drug delivery; cancer immunotherapy; immune checkpoint blockade; extracellular vesicles; immunomodulation; genetic engineering
Ask authors/readers for more resources
Immune checkpoint blockade (ICB) therapy has made significant advancements in cancer treatment, but limited response rates and systemic toxicity hinder its clinical outcomes. Biomaterials have been developed to enhance ICB therapy by increasing tumor antigenicity, reversing immunosuppressive microenvironment, amplifying antitumor immune response, and improving targeted delivery of checkpoint inhibitors. This review discusses current design strategies for biomaterials, their applications in immune modulation and targeted delivery of checkpoint inhibitors for effective ICB therapy, as well as the challenges and future prospects in this field. It is anticipated that this review will contribute to the development of emerging biomaterials for ICB therapy and the advancement of its clinical application.
The immune checkpoint blockade (ICB) therapy has revolutionized the field of cancer treatment, while low response rates and systemic toxicity limit its clinical outcomes. With the rapid advances in nanotechnology and materials science, various types of biomaterials have been developed to maximize therapeutic efficacy while minimizing side effects by increasing tumor antigenicity, reversing immunosuppressive microenviron-ment, amplifying antitumor immune response, and reducing extratumoral distribution of checkpoint inhibitors as well as enhancing their retention within target sites. In this review, we reviewed current design strategies for different types of biomaterials to augment ICB therapy effectively and then discussed present representative biomaterial-assisted immune modulation and targeted delivery of checkpoint inhibitors to boost ICB therapy. Current challenges and future development prospects for expanding the ICB with biomaterials were also summarized. We anticipate this review will be helpful for developing emerging biomaterials for ICB therapy and promoting the clinical application of ICB therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available